- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
The List
Pharmaceutical Executive
It's that time of year again, when Santas everywhere take stock of nice and naughty in order to fill stockings-and magazines make up their lists of hits and has-beens.
It's that time of year again, when Santas everywhere take stock of nice and naughty in order to fill stockings—and magazines make up their lists of hits and has-beens. Here, at Pharm Exec, as we considered such weighty matters as which company's hot, which CEO's in the hot seat, and which ones are yesterday's news, we had to acknowledge the silliness of it all to an industry that makes lifesaving drugs and billion-dollar profits. Honest! Now let's dish.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
